Fig. 2From: Gene therapy for primary immune deficiencies: a Canadian perspectiveViral vector use in gene therapy trials worldwide 2004–2016. Viral vectors account for 67% of the total vectors used for gene therapy clinical trials worldwide. The graph depicts the percentage (%) of AV adenovirus, RV retrovirus, AAV adeno-associated virus and LV lentivirus vector use of the total viral vectorsBack to article page